Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study
AuthorSeamon, Leigh G
Java, James J
Monk, Bradley J
Penson, Richard T
Mannel, Robert S
Leitao, Mario M
Eisenhauer, Eric L
Long, Harry J
Liao, Shu Y
Tewari, Krishnansu S
AffiliationUniv Arizona, Ctr Canc
MetadataShow full item record
PublisherNATURE PUBLISHING GROUP
CitationImpact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study 2017, 118 (2):162 British Journal of Cancer
JournalBritish Journal of Cancer
Rights© 2018 Cancer Research UK. All rights reserved.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractBackground: Based primarily on studies concerning early-stage tumours (treated surgically), and locally advanced disease (treated with chemoradiation), the prognosis for women with adenocarcinoma (AC) or adenosquamous (AS) carcinoma has been reported to be poorer than those with squamous cell carcinoma (SCCA) of the cervix. It is unclear whether differences in prognosis also persist in the setting of recurrent or metastatic disease treated using chemotherapy doublets with or without bevacizumab. Methods: Cases were pooled from three Gynaecologic Oncology Group randomised phase III trials of chemotherapy doublets. Pearson's test was used to evaluate response rate (RR) of AC/AS vs SCCA, Kaplan-Meier method to estimate progression-free survival (PFS) and overall survival (OS), and Cox proportional hazards model to estimate the impact of histology on PFS and OS. Results: Of 781 evaluable patients, 77% (N = 599) had SCCA and 23% (N = 182) AC/AS. There were no significant differences in RRs between histologic subgroups. The adjusted hazard ratio (HR) for death for SCCA vs AC/AS was 1.13 (95% CI 0.93, 1.38 P = 0.23). When comparing SC/AS (N = 661, 85%) to AC alone (N = 120, 15%), the adjusted HR for death was 1.23 (95% CI 0.97, 1.57, P = 0.09). Conclusions: AC/AS and SCCA have similar survival in recurrent or metastatic cervical carcinoma when treated with chemotherapy doublets.
Note12 month embargo; Published online: 28 November 2017 / Creative Commons Attribution-NonCommercial-Share-Alike 3.0
VersionFinal published version
- Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapy.
- Authors: Chen JL, Huang CY, Huang YS, Chen RJ, Wang CW, Chen YH, Cheng JC, Cheng AL, Kuo SH
- Issue date: 2014 Jul
- Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation.
- Authors: Rose PG, Java JJ, Whitney CW, Stehman FB, Lanciano R, Thomas GM
- Issue date: 2014 Nov
- Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.
- Authors: Kokka F, Bryant A, Brockbank E, Powell M, Oram D
- Issue date: 2015 Apr 7
- Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
- Authors: Cripps C, Winquist E, Devries MC, Stys-Norman D, Gilbert R, Head and Neck Cancer Disease Site Group.
- Issue date: 2010 Jun
- Adenosquamous histology predicts a poor outcome for patients with advanced-stage, but not early-stage, cervical carcinoma.
- Authors: Farley JH, Hickey KW, Carlson JW, Rose GS, Kost ER, Harrison TA
- Issue date: 2003 May 1